Skip to main content

Small Molecule Deal Benchmarks in Cardiovascular

Median Upfront
$606M
Range: $330M - $874M
Total Deal Value
$3.0B
Range: $2.0B - $4.1B
Royalty Rate
9.4% - 18.7%
Tiered up to 22.7%
Dev Milestones
$537M
Range: $363M - $713M
Model Your Deal

Market Analysis

Small Molecule therapies in cardiovascular have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in cardiovascular is $606M, with total deal values reaching $3.0B. Development milestones average $537M, while regulatory milestones contribute $684M.

The cardiovascular small molecule landscape is characterized by moderate competitive intensity with renewed interest in novel mechanisms and genetic targets. RNA-based therapies, PCSK9 approaches, and novel anticoagulants are driving a resurgence in cardiovascular deal activity. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule cardiovascular deals range from 9.4% to 18.7% at the base tier, with tiered escalation reaching 13.4%-22.7% on blockbuster sales. Commercial milestones averaging $1.2B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule cardiovascular licensing deal?
Based on our analysis, Phase 2 small molecule licensing deals in cardiovascular average $606M in upfront payments, with a range of $330M to $874M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for small molecule cardiovascular transactions?
The median total deal value for Phase 2 small molecule assets in cardiovascular is $3.0B, ranging from $2.0B to $4.1B. This includes development milestones ($537M), regulatory milestones ($684M), and commercial milestones ($1.2B).
What royalty rates are standard for small molecule deals in cardiovascular?
Base royalty rates for small molecule cardiovascular transactions range from 9.4% to 18.7%, with tiered escalations reaching 13.4%-22.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in small molecule cardiovascular deals?
Small Molecule cardiovascular deals allocate approximately 80% of total deal value to milestones. Development milestones ($537M) make up the largest share, followed by commercial milestones ($1.2B) and regulatory milestones ($684M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Monoclonal Antibody in Cardiovascular

View

Myosin Inhibitor in Cardiovascular

View

Small Molecule in Oncology

View

Small Molecule in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included